Anovel trans-synaptic adhesion complexas a regulator of hypocretin/orexincontrol of arousal
Project Number1R01NS131664-01A1
Former Number1R01NS131664-01
Contact PI/Project LeaderJACKSON, ALEXANDER CHOI Other PIs
Awardee OrganizationUNIVERSITY OF CONNECTICUT STORRS
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
Neurons in the lateral hypothalamic area (LHA) that express the neuropeptide hypocretin/orexin (H/OX) are
critical regulators of sleep-wake architecture, arousal, and motivated behavior. The progressive destruction of
these neurons, and/or disrupted H/OX signaling, in humans causes a devastating, chronic neurological
disease—narcolepsy with cataplexy—which results in disordered wakefulness, loss of muscle control, and late-
onset metabolic effects. Experimental disruption of H/OX signaling in vertebrate animal models recapitulate
many of these symptoms including aberrant sleep-wake states. Despite the clear and conserved role of the H/OX
system in behavioral state control, the molecular and cellular underpinnings of H/OX synaptic function are not
well understood. Thus, the long-term objective of this proposal is to fill this knowledge gap by defining the
molecular machinery underlying the structure and function of H/OX synapses throughout the central nervous
system and illuminating the molecular pathways that drive their behavioral effects. To begin addressing this gap,
this proposal will build off the discovery that mRNA encoding the synaptic organizing protein complement C1q-
like 3 (C1QL3) is uniquely and robustly expressed in H/OX neurons, as identified in a recent transcriptomic
analysis of the LHA. Work in other circuits demonstrated that C1QL3 is important for establishing and maintaining
excitatory synapse density, and it was further shown that C1QL3 global deletion results in deficits in sleep-wake
behavior, reminiscent of features of human narcolepsy. C1QL3 was also shown to bind pre- and postsynaptic
proteins, one of which is also robustly expressed in H/OX neurons. Based on these strong preliminary data, the
hypothesis underlying this proposal is that C1QL3, together with its pre- and postsynaptic binding partners, forms
anovel trans-synaptic adhesion complex, which is necessary for both H/OX synaptic function and its role in
regulating behavioral state. This will be systematically investigated in the following three Specific Aims: 1) In Aim
1, C1QL3 will be visualized in H/OX cell bodies and axons at the light and ultrastructural level using a newly
developed epitope-tagged knockin mouse line, and effects of C1QL3 global and conditional knockout (cKO) and
overexpression on H/OX neuron fiber density and synaptic ultrastructure will be examined. 2) In Aim 2, the impact
of C1QL3 cKO and overexpression on excitatory synaptic function in targets of the H/OX system will be examined
using both in vitro slice electrophysiology and optogenetics, and on sleep-wake behavior using
electroencephalographic recording of vigilance states. 3) In Aim 3, the molecular mechanisms through which
C1QL3 contributes to a trans-synaptic adhesion complex will be dissected using biochemical assays, viral
manipulations, the novel epitope-tagged knockin mouse line, and super-resolution microscopy. This investigation
will not only provide critical mechanistic insight into the basic biology of excitatory synaptic transmission at H/OX
synapses, but also identify anovel molecular pathway through which H/OX signaling may be manipulated as a
therapeutic intervention in chronic neurological and sleep disorders.
Public Health Relevance Statement
PROJECT NARRATIVE
Hypocretin/orexin (H/OX) neurons in the mammalian hypothalamus are critical for coordinating fundamental
behavioral states such as arousal, stress, and motivation, and their dysfunction is implicated in devastating
neurological and sleep disorders, notably narcolepsy with cataplexy. This proposal will use new and innovative
molecular, cellular, and behavioral techniques to dissect the synaptic signaling pathways through which H/OX
neurons shape physiology and behavior. In so doing, we hope to identify targets for therapeutic intervention in
treating and improving the quality of life of patients suffering from neurological and sleep disorders.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
614209054
UEI
WNTPS995QBM7
Project Start Date
01-April-2024
Project End Date
31-March-2029
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$662,485
Direct Costs
$528,067
Indirect Costs
$134,418
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$662,485
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS131664-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS131664-01A1
Patents
No Patents information available for 1R01NS131664-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS131664-01A1
Clinical Studies
No Clinical Studies information available for 1R01NS131664-01A1
News and More
Related News Releases
No news release information available for 1R01NS131664-01A1
History
No Historical information available for 1R01NS131664-01A1
Similar Projects
No Similar Projects information available for 1R01NS131664-01A1